Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

The differentiated R&D pipeline advanced significantly. Key highlights include: The differentiated R&D pipeline advanced significantly. Key highlights include: Global academic influence was underscored by publications in top-tier journals like  The New England Journal of Medicine  (for CM336 in autoimmune hemolytic anemia),  Nature Medicine, and  JAMA  for Stapokibart's pivotal studies. Stapokibart was also included in Chinese treatment guidelines. With robust cash reserves,...

The differentiated R&D pipeline advanced significantly. Key highlights include:

Global academic influence was underscored by publications in top-tier journals like The New England Journal of Medicine (for CM336 in autoimmune hemolytic anemia), Nature Medicine, and JAMA for Stapokibart's pivotal studies. Stapokibart was also included in Chinese treatment guidelines.

With robust cash reserves, strategic financing, and a differentiated clinical pipeline, Keymed is well-positioned to deliver globally competitive, high-quality, affordable, innovative therapies for patients in China and worldwide.

View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-02162hk-reports-strong-interim-2025-results-with-accelerated-commercialization-and-robust-rd-momentum-302539775.html